|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Celera Group (NYSE:CRA), a molecular diagnostics business. |
|---|---|
| Transferring Party | Atria Genetics, Inc., a maker of bone marrow testing products. |
| Sector | Diagnostics |
| Date | October 23, 2007 |
| Analysis Atria's human leukocyte antigen (HLA) testing products are used for identifying potential donors in the matching process for bone marrow transplantation. Gives Celera access to the tissue typing in transplantation and the bone marrow registry markets; Celera will seek to exploit the potential for "next generation" HLA sequencing. Deal value -- $33m. Celera is part of Applera Corp. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |